Gracell Biotechnologies

company

About

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
$100M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2017
Number Of Employee
51 - 100
Operating Status
Active

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$185M
Gracell Biotechnologies has raised a total of $185M in funding over 2 rounds. Their latest funding was raised on Oct 28, 2020 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 28, 2020 Series C $100M 2 Detail
Feb 25, 2019 Series B $85M 3 Detail

Investors

Number of Lead Investors
Number of Investors
3
Gracell Biotechnologies is funded by 3 investors. King Star Capital and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
King Star Capital Series C
Lilly Asia Ventures Series C
Chengdu Miaoji Medical Technology Series B